

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

Last Update: Mar 06, 2025

A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

ClinicalTrials.gov Identifier:

[NCT05622708](#)

Novartis Reference Number:CAIN457I2401

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response (ASDAS-CRP \leq 1.3). Maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120. This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with nr-axSpA who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response Inactive Disease (ID) response (ASDAS-CRP \leq 1.3). The maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120.

Study treatment will be as follows:

- * Open-label Secukinumab PFS (prefilled syringe) will be labeled as AIN457 150mg/1mL
- * Double-blind Secukinumab and Placebo PFS will be labeled as AIN457 150mg/1mL/Placebo.

Study duration will be up to 128 weeks from Baseline.

The treatment duration will be up to 120 weeks with last treatment administration at Week 116.

In the Treatment Period 1 participant will attend a site visit approximately 1 month after Baseline and approximately every 12 weeks thereafter. In the Treatment Period 2 participant will attend site visits approximately every 4 weeks.

Condition
Non-radiographic Axial Spondyloarthritis
Phase
Phase4
Overall Status
Recruiting
Number of Participants
340
Start Date
Mar 28, 2023
Completion Date
Jun 21, 2030
Gender
All
Age(s)
18 Years - 100 Years (Adult, Older Adult)

Interventions

Drug

Placebo

Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.

Drug

Secukinumab

Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116.

Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c.

Eligibility Criteria

Inclusion Criteria:

* Male or non-pregnant, non-lactating female participants at least 18 years of age

* Clinical diagnosis of axSpA AND according to ASAS axSpA criteria:

1. Inflammatory back pain for at least 6 months

2. Onset before 45 years of age

3. Sacroiliitis on MRI (magnetic resonance imaging) (as assessed by central reader) with ≥ 1 SpA feature OR HLA-B-27 positive with ≥ 2 SpA features

* Objective signs of inflammation at screening, evident by either MRI with Sacroiliac Joint inflammation (as assessed by central reader) AND / OR hsCRP $>$ ULN (as defined by the central lab)

* Active axSpA as assessed by total BASDAI ≥ 4 cm (0-10 cm) at baseline.

* Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at baseline.

* Total back pain as measured by VAS (visual analog scale) ≥ 40 mm (0-100 mm) at baseline.

* Participants should have been on at least 2 different NSAIDs (non-steroidal anti-inflammatory drugs) at the highest recommended dose for at least 4 weeks in total prior to baseline with an inadequate response or

failure to respond, or less if therapy had to be withdrawn due to intolerance, toxicity or contraindications.

Exclusion Criteria:

- * Participants with radiographic evidence for sacroiliitis, grade ≥ 2 bilaterally or grade ≥ 3 unilaterally (radiological criterion according to the modified New York diagnostic criteria for AS) as assessed by central reader.
- * Participants taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine).
- * Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor or previous treatment with immunomodulatory biologic agents including those targeting TNF α (tumor necrosis factor α) (unless participants discontinued the treatment with TNF α inhibitor due to a reason other than efficacy \[primary or secondary lack of efficacy, inadequate response\] and only after appropriate wash-out period prior to baseline was observed).
- * History of hypersensitivity to the study drug or its excipients or to drugs of similar chemical classes.
- * Active ongoing inflammatory diseases other than nr-axSpA that might confound the evaluation of the benefit of secukinumab therapy, including uveitis.
- * Active inflammatory bowel disease.
- * History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection.

Belgium

Novartis Investigative Site

Recruiting

Genk,3600,Belgium

Novartis Investigative Site

Recruiting

Gent,9000,Belgium

Novartis Investigative Site

Recruiting

Mons,7000,Belgium

Novartis Investigative Site

Recruiting

Brugge,8000,Belgium

Brazil

Novartis Investigative Site

Recruiting

Juiz de Fora,MG,36010 570,Brazil

Novartis Investigative Site

Recruiting

Porto Alegre,RS,90480-000,Brazil

Novartis Investigative Site

Recruiting

Barretos,Sao Paulo,14784 400,Brazil

Colombia

Novartis Investigative Site

Recruiting

Bucaramanga,Santander,0001,Colombia

Novartis Investigative Site

Recruiting

Barranquilla,080020,Colombia

Novartis Investigative Site

Recruiting

Bogota,110221,Colombia

Novartis Investigative Site

Recruiting

Cundinamarca,111121,Colombia

Novartis Investigative Site

Recruiting

Bogota,Cundinamarca,110111,Colombia

Czechia

Novartis Investigative Site

Recruiting

Praha 2,128 50,Czechia

Novartis Investigative Site

Recruiting

Praha 5,150 06,Czechia

Novartis Investigative Site

Recruiting

Uherske Hradiste,686 01,Czechia

Novartis Investigative Site

Recruiting

Plzen Bory,30599,Czechia

Novartis Investigative Site

Recruiting

Praha 11,14900,Czechia

France

Novartis Investigative Site

Recruiting

Toulouse Cedex 9,31059,France

Novartis Investigative Site

Recruiting

Nice,Cedex1,06001,France

Novartis Investigative Site

Recruiting

Chambray les Tours,37170,France

Novartis Investigative Site

Recruiting

Le Mans,72000,France

Novartis Investigative Site

Recruiting

Paris,75012,France

Novartis Investigative Site

Recruiting

Orleans,45100,France

Germany

Novartis Investigative Site

Recruiting

Berlin,13353,Germany

Novartis Investigative Site

Recruiting

Magdeburg,39110,Germany

Novartis Investigative Site

Recruiting

Bad Doberan,18209,Germany

Novartis Investigative Site

Recruiting

Ratingen,40878,Germany

Novartis Investigative Site

Recruiting

Berlin,12161,Germany

Novartis Investigative Site

Recruiting

Rendsburg,24768,Germany

Novartis Investigative Site

Recruiting

Berlin,13125,Germany

Novartis Investigative Site

Recruiting

Freiburg,79106,Germany

Novartis Investigative Site

Recruiting

Hamburg,22415,Germany

Novartis Investigative Site

Recruiting

Herne,44649,Germany

Hungary

Novartis Investigative Site

Recruiting

Eger,3300,Hungary

Novartis Investigative Site

Recruiting

Kistarcsa,2143,Hungary

Novartis Investigative Site

Recruiting

Szeged,6720,Hungary

Novartis Investigative Site

Recruiting

Veszprem,8200,Hungary

Novartis Investigative Site

Recruiting

Miskolc,H-3526,Hungary

Novartis Investigative Site

Recruiting

Szekesfehervar,Fejer,8000,Hungary

Novartis Investigative Site

Recruiting

Budapest,1023,Hungary

Novartis Investigative Site

Recruiting

Debrecen,4032,Hungary

Israel

Novartis Investigative Site

Recruiting

Kfar Saba,44281,Israel

Novartis Investigative Site

Recruiting

Haifa,3339419,Israel

Novartis Investigative Site

Recruiting

Ramat Gan,52621,Israel

Novartis Investigative Site

Recruiting

Tel Aviv,6423906,Israel

Italy

Novartis Investigative Site

Recruiting

Firenze,FI,50134,Italy

Novartis Investigative Site

Recruiting

Roma,RM,00161,Italy

Novartis Investigative Site

Recruiting

Ancona,AN,60126,Italy

Novartis Investigative Site

Recruiting

Torino,TO,10128,Italy

Novartis Investigative Site

Recruiting

Negrar,VR,37024,Italy

Novartis Investigative Site

Recruiting

Verona,VR,3712,Italy

Malaysia

Novartis Investigative Site

Recruiting

Selangor Darul Ehsan,68100,Malaysia

Novartis Investigative Site

Recruiting

Kuching,Sarawak,93586,Malaysia

Novartis Investigative Site

Recruiting

Kuala Lumpur,59100,Malaysia

Mexico

Novartis Investigative Site

Recruiting

Guadalajara,Jalisco,44650,Mexico

Novartis Investigative Site

Recruiting

Guadalajara,Jalisco,44690,Mexico

Novartis Investigative Site

Recruiting

Merida,Yucatan,97070,Mexico

Novartis Investigative Site

Recruiting

Chihuahua,31000,Mexico

Netherlands

Novartis Investigative Site

Recruiting

Heerlen,6419 pc,Netherlands

Novartis Investigative Site

Recruiting

Maastricht,6229 hx,Netherlands

Novartis Investigative Site

Recruiting

Amsterdam,1105 az,Netherlands

Philippines

Novartis Investigative Site

Recruiting

Makati,Metro Manila,1218,Philippines

Novartis Investigative Site

Recruiting

Manila,1008,Philippines

Poland

Novartis Investigative Site

Recruiting

Bialystok,15-351,Poland

Novartis Investigative Site

Recruiting

Bydgoszcz,85 168,Poland

Novartis Investigative Site

Recruiting

Krakow,30 002,Poland

Novartis Investigative Site

Recruiting

Sochaczew,96-500,Poland

Novartis Investigative Site

Recruiting

Krakow,Malopolskie,30-727,Poland

Novartis Investigative Site

Recruiting

Torun,87-100,Poland

Novartis Investigative Site

Recruiting

Warszawa,02 637,Poland

Romania

Novartis Investigative Site

Recruiting

Brasov,500283,Romania

Novartis Investigative Site

Recruiting

Bucharest,011055,Romania

Novartis Investigative Site

Recruiting

Bucuresti,011172,Romania

Novartis Investigative Site

Recruiting

Cluj Napoca,400006,Romania

Novartis Investigative Site

Recruiting

Sibiu,550245,Romania

Novartis Investigative Site

Recruiting

Suceava,727525,Romania

Thailand

Novartis Investigative Site

Recruiting

Bangkok,10400,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10700,Thailand

Turkey

Novartis Investigative Site

Recruiting

Pendik Istanbul,34899,Turkey

Novartis Investigative Site

Recruiting

Adana,01160,Turkey

Novartis Investigative Site

Recruiting

Konya,42080,Turkey

Vietnam

Novartis Investigative Site

Recruiting

Ho Chi Minh,700000,Vietnam

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct05622708>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05622708>
2. [#trial-eligibility](#)
3. <tel:+41613241111>
4. <mailto:novartis.email@novartis.com>